---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-194715"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2023-07-26T23:59:59+00:00"
generated_at: "2026-06-13T02:13:52.874615+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Alnylam partners with Roche on zilebesiran; receives $310M upfront, up to $2.5B milestones

## Summary
- Upfront cash payment of $310 million; potential total deal value up to $2.8 billion including development, regulatory, and sales milestones.
- Alnylam and Roche to co-develop and co-commercialize zilebesiran in US (50/50 profit share); Roche gets exclusive ex-US rights with low double-digit royalties.
- Alnylam leads joint clinical development plan including cardiovascular outcomes trial; development costs split 40% Alnylam, 60% Roche.
- Zilebesiran is an investigational RNAi therapeutic for hypertension, currently in Phase 2; Phase 1 showed durable blood pressure reduction up to 6 months.

## SEC filing metadata
- accession: 0001193125-23-194715
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2023-07-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/0001193125-23-194715-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-194715
- JSON: https://secwatch.observer/filing/0001193125-23-194715.json
- Plain text: https://secwatch.observer/filing/0001193125-23-194715.txt

## Key facts
- Material Agreements
  ALNYLAM PHARMACEUTICALS, INC. entered into Collaboration and License Agreement with F. Hoffmann-La Roche Ltd. and Genentech, Inc. valued at $310 million (effective 2023-07-21).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: F. Hoffmann-La Roche Ltd. and Genentech, Inc.
  - Value: $310 million
  - Effective: 2023-07-21
  source text: On July 21, 2023 (the “ Effective Date ”), Alnylam Pharmaceuticals, Inc. (the “ Company ”), entered into a Collaboration and License Agreement (the “ Agreement ”) with F. Hoffmann-La Roche Ltd. (“ Roche Basel ”) and Genentech, Inc. (“ Genentech ,” each of Roche Basel and Genentech, individually and collectively, “ Roche ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/0001193125-23-194715-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.